Mark S. Blumenkranz - 11 Jun 2024 Form 4 Insider Report for KALA BIO, Inc. (KALA)

Reporting relationship: Director
Issuer ticker: KALA
Reported as of: 11 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2024, 20:00:06 UTC
Prior SEC filing: 13 Jul 2023
Source filing: View source filing
Reporting owner signature: /s/ Mary Reumuth, Attorney-in-Fact

Key filing fact

Mark S. Blumenkranz filed Form 4 for KALA BIO, Inc. (KALA) on 12 Jun 2024.

Key facts

This page summarizes Mark S. Blumenkranz's Form 4 filing for KALA BIO, Inc. (KALA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2024, 20:00.

Change

Previous filing in this sequence was filed on 13 Jul 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KALA transaction

Common Stock

Award

Transaction value: $0
Shares: +1,400
Change %: +12%
Price: $0.000000
Shares after: 13,091
Date: 11 Jun 2024
Ownership: Direct
Footnotes: F1, F2

KALA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 168,454
Date: 11 Jun 2024
Ownership: See footnote
Footnotes: F3

KALA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,276
Date: 11 Jun 2024
Ownership: See footnote
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KALA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +3,150
Change %
Price: $0.000000
Shares after: 3,150
Date: 11 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,150
Exercise price: $6.18
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024.

Footnote F2

Includes 6,615 unvested RSUs.

Footnote F3

These securities are held directly by Lagunita Biosciences, LLC ("Lagunita"). The reporting person is a managing partner of Lagunita and may be deemed to have beneficial ownership over the Lagunita Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Footnote F4

These securities are held directly by Garland Investments, L.P. ("Garland"). The reporting person is a managing partner of Garland and may be deemed to have beneficial ownership over the Garland Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Footnote F5

This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024.